Study of VigiBase Database of Uppsala Monitoring Centre

doi:10.19803/j.1672-8629.2020.10.06

Abstract

Abstract: Objective To study the structure, tools and functions of VigiBase, a database managed by the Uppsala Monitoring Centre (UMC), and to provide reference for improving the database of adverse drug reactions (ADRs) in China. Methods The structure and functions of VigiBase were analyzed by consulting literature and searching VigiBase. Results VigiBase was the largest database of individual case safety reports (ICSRs) in the world. UMC evaluated the quality of ICSRs via VigiGrade, inspected the duplicate reports via VigiMatch, detected drug safety signals via VigiRank, and also provided VigiLyze, VigiFlow, VigiAccess and other tools for member states to manage ICSRs and retrieve data from VigiBase. Conclusion The assessment of report quality and drug safety signal detection need to be improved in China.

Key words: WHO programme for international drug monitoring, Uppsala Monitoring Centre, database, vigivase database

CLC Number:

R951

ZHANG Wei, WEI Fuqian, YANG Yue. Study of VigiBase Database of Uppsala Monitoring Centre[J]. Chinese Journal of Pharmacovigilance, 2020, 17(10): 676-680.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.2020.10.06

https://zgywjj.magtechjournal.com/EN/Y2020/V17/I10/676

References

[1] Jacques Caron, Michaël Rochoy, Louise Gaboriau, et al.The History of Ppharmacovigilance[J].Therapie, 2016(71):129-134.
[2] Peng LL, Wang D, Shen L, et al.Development and Origin of Pharmacovigilance[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2016, 13(7): 410-413.
[3] Uppsala Monitoring Centre. The story of UMC and the WHO Programme[EB/OL].(2018-10-11)[2020-01-27].https://www. who-umc.org/global-pharmacovigilance/who-programme/the- story-of-umc-and-the-who-programme/.
[4] Overview of the development of the WHO International Drug Monitoring Cooperation Program[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 1999(1): 47-48.
[5] Uppsala Monitoring Centre. VigiMethods[EB/OL].(2017-01-10) [2020-01-27].https://www.who-umc.org/vigibase/vigilyze/ vigimethods/.
[6] Uppsala Monitoring Centre. Better Signal Detection with VigiRank [EB/OL].(2018-04-18)[2020-01-27].https://www.who-umc.org/ media/164251/uppsalareports78web.pdf.
[7] Philip Michael Tregunno, Dorthe Bech Fink, Cristina Fernandez- Fernandez, et al.Performance of Probabilistic Method to Detect Duplicate Individual Case Safety Reports[J]. Drug Safety, 2014, 37(4):249-258.
[8] Uppsala Monitoring Centre. WHO Drug Global[EB/OL].(2019-08- 30)[2020-01-27].https://www.who-umc.org/whodrug/whodrug- portfolio/whodrug-global/%E5%85%B3%E4%BA%8Ewhodrug- global/.
[9] Uppsala Monitoring Centre. Being a member of the WHO Programme for International Drug Monitoring[EB/OL].(2020-01-16)[2020- 01-27].https://www.who-umc.org/media/1434/being-a-member.pdf.
[10] Uppsala Monitoring Centre. Individual Case Safety Reports and VigiBase- the vital importance of quality[EB/OL].(2012-03) [2020-01-27].https://www.who-umc.org/media/163807/vigibase- the-vital-importance-of-quality-2017.pdf.
[11] Uppsala Monitoring Centre. WHODrug Global Chinese[EB/OL]. (2019-10-10)[2020-01-27].https://www.who-umc.org/whodrug/ whodrug-portfolio/whodrug-global/%E5%85%B3%E4%BA%- 8Ewhodrug-global/%E5%85%B3%E4%BA%8Ewhodrug-global- chinese/.
[12] Tomas Bergvall, G. Niklas Norén, Marie Lindquist. VigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues[J]. Drug Safety, 2014, 37(1):65-77.
[13] Shi W T.Identification and Elimination of Duplicate Reports in Signal Detection of Adverse Drug Reaction[D]. The Second Military Medical University, 2018.
[14] Uppsala Monitoring Centre.VigiLyze[EB/OL][2020-01-27].https:// www.who-umc.org/VigiBase/VigiLyze/.
[15] Kristina Johansson, Sten Olsson, Björn Hellman, et al.An Analysis of Vigimed, a Global E-Mail System for the Exchange of Pharmacovigilance Information[J]. Drug Safety, 2007, 30(10): 883-889.
[16] Caster Ola, Sandberg Lovisa, Bergvall Toma, et al.VigiRank for statistical signal detection in pharmacovigilance: First results from prospective real-world use[J].Pharmacoepidemiology and Ddrug Ssafety, 2017, 26(8):1006-1010.
[17] Uppsala Monitoring Centre. What is a signal?[EB/OL].(2019- 06-12)[2020-01-27].https://www.who-umc.org/research-scientific- development/signal-detection/what-is-a-signal/.
[18] Wei J.Research on Drug Safety Monitoring System[D]. Shenyang Pharmaceutical University, 2011.
[19] Liu W, Li XL, Cheng G, et al.Study on the Evaluation for Quality of Adverse Drug Reaction Reports in China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(9): 561-563, 566.
[20] Hou YF, Liu CL, Song HB, et al.Optimized Signal Detection Model in Adverse Drug Reaction Monitoring System[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2016, 13(7): 408-409, 421.